Indeed, AMPK is a novel molecule that can treat NAFLD and NASH by inhibiting lipogenesis through suppressing SREBP1/2 and upregulating PPARα (Strzyz 2020; Tian et al. This evidence concerns the gene SREBF1 and metabolic dysfunction-associated steatohepatitis.